Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center

A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.

A panel of experts discuss the role of odronextamab.

A panel of experts discuss the incidence, severity, and management of AEs associated with CAR Tcell therapy.

A panel of experts discuss risk of secondary malignancies in heavily pre-treated populations.

A panel of experts discusses their individual approaches to bridging therapy in R/R DLBCL for patients eligible for CART

A panel of experts discuss current challenges for use of CAR T in R/R DLBCL.

Bradley Hunter, MD, and Fred Locke, MD, and Elizabeth Budde, MD, PhD, share insights surrounding treatment considerations for CD19 targeting.

Dr Hunter discusses the decision making process around second-line therapies for transplant-ineligible patients, and further key clinical study data.

Multiple studies analyzing considerations for transplant-ineligible patients receiving second-line treatment with CAR T-cell therapy are discussed by key opinion leaders.

An examination of results from key studies in the DLBCL landscape are conducted by Dr Fred Locke.

Medical experts from various prestigious oncology institutions drive a conversation around referral patterns in the DLBCL treatment landscape.

Medical experts highlight second-line options for treating patients with DLBCL.

Key opinion leaders Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the evolving treatment landscape of follicular lymphoma and look toward future evolutions in the field.

Centering discussion on a second patient scenario of follicular lymphoma, key opinion leaders consider best therapy for patients with early or aggressive relapse.

A brief discussion on the respective roles of EZH2- and PI3K-targeted therapies in patients with relapsed/refractory follicular lymphoma.

Switching focus back to relapsed/refractory follicular lymphoma, Sameh Gaballa, MD, and Matthew Lunning, DO, FACP, consider the list of available treatment options in this setting.

Before closing out their discussion on first-line management of follicular lymphoma, experts consider the importance of patient monitoring and discuss the diminished role of maintenance therapy.

A brief review of BTK inhibitor therapy and its potential role within the relapsed/refractory follicular lymphoma treatment landscape.

Centering discussion on a patient scenario of relapsed/refractory follicular lymphoma, key opinion leaders consider how they would select best available therapy in this setting.

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.

Before closing out their discussion on the relapsed/refractory setting of diffuse large B-cell lymphoma, panelists identify best practices in bridging therapy.

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.